Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ZEVRA THERAPEUTICS, INC.KMPH · Entity 5212 | Director | June 30, 2019 | July 02, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ZEVRA THERAPEUTICS, INC.
Report date June 30, 2019 · Filed July 02, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,727 |
Reported balance
After 2019-06-30 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2019-06-30 · Grant · Acquired 8,214 · Balance 31,727 F1: Grant to the Reporting Person of a fully vested restricted stock award ("RSA") under the Issuer's 2014 Equity Incentive Plan. The RSA was granted to the Reporting Person in lieu of the quarterly cash compensation payable to the Reporting Person pursuant to the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy. |
| Common StockSEC Table I · non-derivative | Direct | 7,373 |
Reported balance
Holding disclosure · report date 2019-06-30 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 7,373 F2: Held jointly with spouse. |
| Common StockSEC Table I · non-derivative | IndirectBy Garrett Bancshares, LTD | 91,687 |
Reported balance
Holding disclosure · report date 2019-06-30 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 91,687 F3: The Reporting Person is the Vice-President of Garrett Bancshares, LTD and may be deemed to have shared voting and dispositive power over, and be deemed to be indirect beneficial owner of, the shares directly held by Garrett Bancshares, LTD. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant to the Reporting Person of a fully vested restricted stock award ("RSA") under the Issuer's 2014 Equity Incentive Plan. The RSA was granted to the Reporting Person in lieu of the quarterly cash compensation payable to the Reporting Person pursuant to the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy.
F2: Held jointly with spouse.
F3: The Reporting Person is the Vice-President of Garrett Bancshares, LTD and may be deemed to have shared voting and dispositive power over, and be deemed to be indirect beneficial owner of, the shares directly held by Garrett Bancshares, LTD.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2019 Filed Jul 2, 2019 21:04 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantCommon Stock | 8,214 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-013394 · rdgdoc.xml · nonDerivative · entry 1 Thompson Danny L · CIK 0001638363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,727 F1 · shares: Grant to the Reporting Person of a fully vested restricted stock award ("RSA") under the Issuer's 2014 Equity Incentive Plan. The RSA was granted to the Reporting Person in lieu of the quarterly cash compensation payable to the Reporting Person pursuant to the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy. Read SEC document |
| May 10, 2019 Filed May 15, 2019 00:39 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantCommon Stock | 8,873 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-009883 · rdgdoc.xml · nonDerivative · entry 1 Thompson Danny L · CIK 0001638363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,513 F1 · shares: Grant to the Reporting Person of a fully vested restricted stock award ("RSA") under the Issuer's 2014 Equity Incentive Plan. The RSA was granted to the Reporting Person in lieu of the quarterly cash compensation payable to the Reporting Person pursuant to the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy. Read SEC document |
| April 24, 2019 Filed Apr 26, 2019 21:01 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001437749-19-008065 · rdgdoc.xml · derivative · entry 1 Thompson Danny L · CIK 0001638363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-04-23 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Market on the date of grant, April 24, 2019. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's third amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| May 22, 2018 Filed May 24, 2018 20:05 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $6.10 | $0.00 |
DisclosureSEC source: 0001437749-18-010653 · rdgdoc.xml · derivative · entry 1 Thompson Danny L · CIK 0001638363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-05-21 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Market on the date of grant, May 22, 2018. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| March 23, 2018 Filed Mar 27, 2018 21:22 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | Exercise / conversionStock Option (right to buy) · Derivative | 3,333 | $0.00 Strike: $4.65 | $0.00 |
DisclosureSEC source: 0001437749-18-005591 · rdgdoc.xml · derivative · entry 5 Thompson Danny L · CIK 0001638363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,333 shares Expires 2018-03-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's Incentive Stock Plan. The shares subject to the option are fully vested. Read SEC document |
| March 23, 2018 Filed Mar 27, 2018 21:22 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | Tax withholdingCommon Stock | 2,026 | $7.65 | $15,498.90 |
DisclosureSEC source: 0001437749-18-005591 · rdgdoc.xml · nonDerivative · entry 2 Thompson Danny L · CIK 0001638363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,640 Read SEC document |
| March 23, 2018 Filed Mar 27, 2018 21:22 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | Exercise / conversionCommon Stock | 3,333 | $4.65 | $15,498.45 |
DisclosureSEC source: 0001437749-18-005591 · rdgdoc.xml · nonDerivative · entry 1 Thompson Danny L · CIK 0001638363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 23, 2017 Filed May 24, 2017 21:32 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.95 | $0.00 |
DisclosureSEC source: 0001437749-17-010012 · rdgdoc.xml · derivative · entry 1 Thompson Danny L · CIK 0001638363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-05-22 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Market on the date of grant, May 23, 2017. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.